BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-9; discussion 459-61. [PMID: 15319716 DOI: 10.1097/01.sla.0000137129.98894.42] [Cited by in Crossref: 309] [Cited by in F6Publishing: 257] [Article Influence: 18.2] [Reference Citation Analysis]
Number Citing Articles
1 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 237] [Article Influence: 35.3] [Reference Citation Analysis]
2 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989. [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
3 Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, Jang HJ, Charnsangavej C, Taouli B. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15:972-978. [PMID: 18236118 DOI: 10.1245/s10434-007-9685-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
4 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
5 Taketomi A, Shirabe K, Toshima T, Morita K, Hashimoto N, Kayashima H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. The long-term outcomes of patients with hepatocellular carcinoma after living donor liver transplantation: a comparison of right and left lobe grafts. Surg Today 2012;42:559-64. [DOI: 10.1007/s00595-011-0086-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
6 Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl. 2009;15:1861-1866. [PMID: 19938113 DOI: 10.1002/lt.21940] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
7 Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-432. [PMID: 17597707 DOI: 10.1038/ncponc0844] [Cited by in Crossref: 191] [Cited by in F6Publishing: 169] [Article Influence: 13.6] [Reference Citation Analysis]
8 Morioka D, Tanaka K, Matsuo K, Takeda K, Ueda M, Sugita M, Nagano Y, Endo I, Sekido H, Togo S, Shimada H. Applicability of the Milan Criteria for Determining Liver Transplantation as a First-Line Treatment for Hepatocellular Carcinoma. Ann Surg Oncol 2006;13:1500-10. [DOI: 10.1245/s10434-006-9204-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
9 Jonas S, Mittler J, Pascher A, Schumacher G, Theruvath T, Benckert C, Rudolph B, Neuhaus P. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl. 2007;13:896-903. [PMID: 17538994 DOI: 10.1002/lt.21189] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
10 Chao SD, Roberts JP, Farr M, Yao FY. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant 2007;7:1594-600. [PMID: 17430396 DOI: 10.1111/j.1600-6143.2007.01800.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
11 Tsoulfas G, Agorastou P, Tooulias A, Marakis GN. Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. Int Surg 2014;99:779-86. [PMID: 25437587 DOI: 10.9738/INTSURG-D-13-00122.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl. 2011;17 Suppl 2:S98-108. [PMID: 21954097 DOI: 10.1002/lt.22391] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
13 Balci D, Dayangac M, Yaprak O, Akin B, Duran C, Killi R, Yuzer Y, Tokat Y. Living donor liver transplantation for hepatocellular carcinoma: a single center analysis of outcomes and impact of different selection criteria: Living donor liver transplantation for hepatocellular carcinoma. Transplant International 2011;24:1075-83. [DOI: 10.1111/j.1432-2277.2011.01311.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
14 Nathan H, Bridges JF, Schulick RD, Cameron AM, Hirose K, Edil BH, Wolfgang CL, Segev DL, Choti MA, Pawlik TM. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol 2011;29:619-25. [PMID: 21205759 DOI: 10.1200/JCO.2010.30.8650] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
15 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
16 Mendizabal M, Reddy KR. Current Management of Hepatocellular Carcinoma. Medical Clinics of North America 2009;93:885-900. [DOI: 10.1016/j.mcna.2009.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
17 Cunningham SC, Tsai S, Marques HP, Mira P, Cameron A, Barroso E, Philosophe B, Pawlik TM. Management of Early Hepatocellular Carcinoma in Patients with Well-Compensated Cirrhosis. Ann Surg Oncol 2009;16:1820-31. [DOI: 10.1245/s10434-009-0364-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
18 Foltys D, Zimmermann T, Heise M, Kaths M, Lautem A, Wisser G, Weiler N, Hoppe-Lotichius M, Hansen T, Otto G. Liver transplantation for hepatocellular carcinoma--is there a risk of recurrence caused by intraoperative blood salvage autotransfusion? Eur Surg Res. 2011;47:182-187. [PMID: 21986299 DOI: 10.1159/000330746] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
19 Olsen SK, Brown RS Jr. Live donor liver transplantation: current status. Curr Gastroenterol Rep 2008;10:36-42. [PMID: 18417041 DOI: 10.1007/s11894-008-0007-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
20 Fouzas I, Sotiropoulos G, Lang H, Nadalin S, Beckebaum S, Sgourakis G, Saner F, Radtke A, Papanikolaou V, Baba H, Paul A, Broelsch C, Malagó M. Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria. Transplantation Proceedings 2008;40:3185-8. [DOI: 10.1016/j.transproceed.2008.08.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
21 Thuluvath PJ, Maheshwari A, Thuluvath NP, Nguyen GC, Segev DL. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus: Post-LT Survival for HCC and Impact of HCV. Liver Transpl 2009;15:754-62. [DOI: 10.1002/lt.21744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
22 Kwak BJ, Kim DG, Han JH, Choi HJ, Bae SH, You YK, Choi JY, Yoon SK. Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience. Ann Surg Treat Res 2018;95:267-77. [PMID: 30402445 DOI: 10.4174/astr.2018.95.5.267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Panda D. Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S43-9. [PMID: 25755610 DOI: 10.1016/j.jceh.2014.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Hwang S, Kim Y, Kim DK, Ahn C, Moon D, Kim K, Ha T, Song G, Jung D, Kim HR, Park G, Namgoong J, Yoon S, Jung S, Park SI, Lee S. Resection of Pulmonary Metastases from Hepatocellular Carcinoma following Liver Transplantation. World J Surg 2012;36:1592-602. [DOI: 10.1007/s00268-012-1533-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
25 Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S277-S282. [PMID: 15508095 DOI: 10.1007/978-1-60327-376-3_19] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Imai K, Beppu T, Nakayama Y, Ishiko T, Horino K, Komori H, Masuda T, Hayashi H, Okabe H, Baba Y, Watanabe M, Takamori H, Awai K, Yamashita Y, Baba H. Preoperative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy. J Surg Oncol 2009;100:121-6. [PMID: 19402077 DOI: 10.1002/jso.21302] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sun X, Zhang Y, Lyu N, Li X, Chen M, Zhao M. The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up? Med Sci Monit 2019;25:4941-51. [PMID: 31270311 DOI: 10.12659/MSM.916451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lee CH, Brubaker LM, Gerber DA, Ku YM, Kim YH, Shin SS, Semelka RC. MRI findings of recurrent hepatocellular carcinoma after liver transplantation: preliminary results. J Magn Reson Imaging. 2011;33:1399-1405. [PMID: 21591009 DOI: 10.1002/jmri.22326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
29 Greig PD, Geier A, D'Alessandro AM, Campbell M, Wright L. Should we perform deceased donor liver transplantation after living donor liver transplantation has failed? Liver Transpl 2011;17 Suppl 2:S139-46. [PMID: 21563294 DOI: 10.1002/lt.22328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
30 Freeman RB. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. Liver Transpl. 2006;12:S8-13. [PMID: 17051567 DOI: 10.1002/lt.20936] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
31 Jiang XZ, Yan LN, Wen TF, Li B, Zeng Y, Zhao JC, Wang WT, Yang JY, Xu MQ, Chen ZY, Ma YK, Li FG, Gong G. University of California at San Francisco criteria can be applied to living donor liver transplantation for hepatocellular carcinoma: single-center preliminary results in 27 patients. Transplant Proc 2008;40:1476-80. [PMID: 18589132 DOI: 10.1016/j.transproceed.2008.02.087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, Bhoori S, Lee SG. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15:1001-1007. [PMID: 18236119 DOI: 10.1245/s10434-007-9559-5] [Cited by in Crossref: 184] [Cited by in F6Publishing: 175] [Article Influence: 14.2] [Reference Citation Analysis]
33 Volk ML, Marrero JA, Lok AS, Ubel PA. Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation 2006;82:1136-9. [PMID: 17102762 DOI: 10.1097/01.tp.0000245670.75583.3d] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
34 Sandhu L, Sandroussi C, Guba M, Selzner M, Ghanekar A, Cattral MS, Mcgilvray ID, Levy G, Greig PD, Renner EL, Grant DR. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: Comparable survival and recurrence. Liver Transpl 2012;18:315-22. [DOI: 10.1002/lt.22477] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
35 Hermann HC, Klapp BF, Danzer G, Papachristou C. Gender-specific differences associated with living donor liver transplantation: a review study. Liver Transpl 2010;16:375-86. [PMID: 20209639 DOI: 10.1002/lt.22002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
36 Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T, Shimada M, Maehara Y. Extended Indication for Living Donor Liver Transplantation in Patients With Hepatocellular Carcinoma. Transplantation 2007;83:893-9. [DOI: 10.1097/01.tp.0000259015.46798.ec] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 8.4] [Reference Citation Analysis]
37 Nanashima A, Tobinaga S, Masuda J, Miyaaki H, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Selecting treatment for hepatocellular carcinoma based on the results of hepatic resection and local ablation therapy. J Surg Oncol 2010;101:481-5. [PMID: 20191611 DOI: 10.1002/jso.21523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
38 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res 2018;48:E87-97. [PMID: 28656680 DOI: 10.1111/hepr.12932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Hasegawa K, Kokudo N. Surgical treatment of hepatocellular carcinoma. Surg Today 2009;39:833-43. [PMID: 19784720 DOI: 10.1007/s00595-008-4024-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
40 Tremosini S, Reig M, de Lope CR, Forner A, Bruix J. Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis. 2010;42 Suppl 3:S242-S248. [PMID: 20547310 DOI: 10.1016/s1590-8658(10)60512-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
41 Renz JF, Kin CJ, Saggi BH, Emond JC. Outcomes of Living Donor Liver Transplantation. Transplantation of the Liver. Elsevier; 2005. pp. 713-24. [DOI: 10.1016/b978-0-7216-0118-2.50052-5] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
42 Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, Harada N, Morita K, Toshima T, Motomura T. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19:1082-1090. [PMID: 28888776 DOI: 10.1016/j.hpb.2017.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
43 Sugawara Y, Makuuchi M. Living donor liver transplantation: present status and recent advances. British Medical Bulletin 2005;75-76:15-28. [DOI: 10.1093/bmb/ldh058] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
44 Chun YS, Ribero D, Abdalla EK, Madoff DC, Mortenson MM, Wei SH, Vauthey JN. Comparison of two methods of future liver remnant volume measurement. J Gastrointest Surg. 2008;12:123-128. [PMID: 17924174 DOI: 10.1007/s11605-007-0323-8] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 4.9] [Reference Citation Analysis]
45 Malagó M, Sotiropoulos GC, Nadalin S, Valentin-Gamazo C, Paul A, Lang H, Radtke A, Saner F, Molmenti E, Beckebaum S. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl. 2006;12:934-940. [PMID: 16528715 DOI: 10.1002/lt.20677] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
46 Lee S, Ahn C, Ha T, Moon D, Choi K, Song G, Chung D, Park G, Yu Y, Choi N, Kim K, Kim K, Hwang S. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci. 2010;17:539-547. [PMID: 19727542 DOI: 10.1007/s00534-009-0167-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
47 Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Liver Cancer Working Group report. Jpn J Clin Oncol. 2010;40 Suppl 1:i19-i27. [PMID: 20870915 DOI: 10.1093/jjco/hyq123] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
48 Liu CL, Fan ST. Adult-to-adult live-donor liver transplantation: the current status. J Hepatobiliary Pancreat Surg. 2006;13:110-116. [PMID: 16547671 DOI: 10.1007/s00534-005-1016-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
49 Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim GS, Kim SJ, Paik SW, Lee SK. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc. 2014;46:726-729. [PMID: 24767334 DOI: 10.1016/j.transproceed.2013.11.037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
50 Foltys D, Zimmermann T, Kaths M, Strempel M, Heise M, Hoppe-lotichius M, Weiler N, Scheuermann U, Ruckes C, Hansen T, Pitton M, Otto G. Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection according to the intention-to-treat principle. Clin Transplant 2014;28:37-46. [DOI: 10.1111/ctr.12273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
51 Hackl C, Schlitt HJ, Kirchner GI, Knoppke B, Loss M. Liver transplantation for malignancy: current treatment strategies and future perspectives. World J Gastroenterol. 2014;20:5331-5344. [PMID: 24833863 DOI: 10.3748/wjg.v20.i18.5331] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
52 Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Yamashita K, Kamiyama T, Matsushita M, Todo S. Living-donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006;13:393-7. [DOI: 10.1007/s00534-005-1079-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
53 Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Park CS, Park YH, Kang SH, Jung BH, Lee SG. Long-term survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma. Transplant Proc 2013;45:3032-4. [PMID: 24157029 DOI: 10.1016/j.transproceed.2013.08.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2007;13:S48-S54. [PMID: 17969069 DOI: 10.1002/lt.21334] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.4] [Reference Citation Analysis]
55 Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009;23 Suppl 21:49-60. [PMID: 19930317 DOI: 10.1111/j.1399-0012.2009.01110.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
56 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
57 Hwang S, Ahn C, Kim K, Moon D, Ha T, Song G, Jung D, Park G, Yu Y, Park P, Choi Y, Kim K, Lim Y, Lee HC, Yu E, Lee S. Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation. J Gastrointest Surg 2011;15:971-81. [DOI: 10.1007/s11605-011-1467-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
58 Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 2010;17:527-32. [PMID: 19707711 DOI: 10.1007/s00534-009-0162-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
59 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol. 2015;21:3826-3842. [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
60 Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94:78-86. [PMID: 17016793 DOI: 10.1002/bjs.5528] [Cited by in Crossref: 159] [Cited by in F6Publishing: 156] [Article Influence: 11.4] [Reference Citation Analysis]
61 Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantation. Hepatology 2011;53:1570-9. [DOI: 10.1002/hep.24231] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 9.6] [Reference Citation Analysis]
62 Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology. 2011;81 Suppl 1:111-115. [PMID: 22212944 DOI: 10.1159/000333270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
63 Neuhaus P. Live donor/split liver grafts for adult recipients: When should we use them? Liver Transpl 2005;11:S6-9. [DOI: 10.1002/lt.20604] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
64 Wan P, Xia Q, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ. Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience. J Cancer Res Clin Oncol 2014;140:341-8. [PMID: 24374832 DOI: 10.1007/s00432-013-1576-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
65 Lang H, Broelsch CE. [Liver resection and transplantation for hepatic tumors]. Internist (Berl) 2007;48:30-9. [PMID: 17195060 DOI: 10.1007/s00108-006-1780-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Tsoulfas G, Mekras A, Agorastou P, Kiskinis D. Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg. 2012;82:510-517. [PMID: 22548726 DOI: 10.1111/j.1445-2197.2012.06079.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
67 Togashi J, Sugawara Y, Aoki T, Tamura S, Kaneko J, Nakajima J, Sano A, Kokudo N. Resection of lung metastases from hepatocellular carcinoma after living donor liver transplantation: report of two cases. Surg Today. 2011;41:1294-1297. [PMID: 21874434 DOI: 10.1007/s00595-010-4487-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
68 Saeki I, Terai S, Fujisawa K, Takami T, Yamamoto N, Matsumoto T, Hirose Y, Murata Y, Yamasaki T, Sakaida I. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol. 2013;48:738-750. [PMID: 23011081 DOI: 10.1007/s00535-012-0675-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
69 Hu Z, Qian Z, Wu J, Zhou J, Zhang M, Zhou L, Zheng S. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation. Clin Res Hepatol Gastroenterol 2016;40:315-26. [PMID: 26382281 DOI: 10.1016/j.clinre.2015.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
70 Marubashi S, Dono K, Sugita Y, Asaoka T, Hama N, Gotoh K, Miyamoto A, Takeda Y, Nagano H, Umeshita K, Monden M. Alpha-fetoprotein mRNA Detection in Peripheral Blood for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation Proceedings 2006;38:3640-2. [DOI: 10.1016/j.transproceed.2006.10.067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
71 Tamura S, Sugawara Y, Kokudo N. Section 4. Further Expanding the Criteria for HCC in Living Donor Liver Transplantation: The Tokyo University Experience. Transplantation 2014;97:S17-20. [DOI: 10.1097/01.tp.0000446268.26771.59] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
72 Najjar M, Agrawal S, Emond JC, Halazun KJ. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;5:17-28. [PMID: 29404284 DOI: 10.2147/jhc.s86792] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
73 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
74 Tsoulfas G, Kawai T, Elias N, Ko SC, Agorastou P, Cosimi AB, Hertl M. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011;46:249-56. [PMID: 20711612 DOI: 10.1007/s00535-010-0302-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
75 Pomfret EA, Lodge JP, Villamil FG, Siegler M. Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations. Liver Transpl. 2011;17 Suppl 2:S128-S132. [PMID: 21656657 DOI: 10.1002/lt.22356] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
76 Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Maehara Y. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008;15:124-30. [DOI: 10.1007/s00534-007-1296-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
77 Takayama T, Makuuchi M, Hasegawa K. Single HCC smaller than 2 cm: surgery or ablation?: surgeon’s perspective. J Hepatobiliary Pancreat Sci. 2010;17:422-424. [PMID: 19936598 DOI: 10.1007/s00534-009-0239-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
78 Cucchetti A, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, Grazi GL, Golfieri R, Grigioni WF, Pinna AD. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52:880-888. [PMID: 20409605 DOI: 10.1016/j.jhep.2009.12.037] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 10.0] [Reference Citation Analysis]
79 Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol. 2008;14:4445-4453. [PMID: 18680222 DOI: 10.3748/wjg.14.4445] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
80 Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007;41:839-54. [DOI: 10.1097/mcg.0b013e318060ac52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
81 Majno P, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language. Liver Transpl. 2006;12:896-898. [PMID: 16721768 DOI: 10.1002/lt.20808] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
82 Fan ST. Live-donor liver transplantation for hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S275-6. [PMID: 17877494 DOI: 10.1111/j.1872-034X.2007.00196.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999. [PMID: 22429190 DOI: 10.1111/j.1365-2036.2012.05060.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
84 Yamasaki T, Saeki I, Harima Y, Zaitsu J, Maeda M, Tanimoto H, Iwamoto T, Hidaka I, Urata Y, Ishikawa T, Takami T, Yamaguchi Y, Uchida K, Terai S, Sakaida I. Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma. J Gastroenterol 2012;47:715-22. [DOI: 10.1007/s00535-012-0537-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
85 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016;22:7252-63. [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
86 Sotiropoulos GC, Lang H, Sgourakis G, Nadalin S, Molmenti EP, Radtke A, Paul A, Beckebaum S, Saner FH, Baba HA, Gerken G, Malagó M, Broelsch CE. Liberal Policy in Living Donor Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned. Dig Dis Sci 2009;54:377-84. [DOI: 10.1007/s10620-008-0319-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
87 Lee SG, Moon DB. Living donor liver transplantation for hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:165-179. [PMID: 22941020 DOI: 10.1007/978-3-642-16037-0_11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
88 Alshahrani AA, Hwang S, Song GW, Moon DB, Jung DH, Ahn CS, Kim KH, Ha TY, Park GC, Ha SM, Park YH, Lee SG. Management of very late peritoneal metastasis of hepatocellular carcinoma 10 years after liver transplantation: Lessons from two cases. Ann Hepatobiliary Pancreat Surg 2018;22:136-43. [PMID: 29896574 DOI: 10.14701/ahbps.2018.22.2.136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
89 Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J, Matsui Y, Togashi J, Akahane M, Makuuchi M. Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. Hepatol Res. 2010;40:278-286. [PMID: 20070400 DOI: 10.1111/j.1872-034x.2009.00591.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
90 Bonadio I, Colle I, Geerts A, Smeets P, Berardi G, Praet M, Rogiers X, de Hemptinne B, Van Vlierberghe H, Troisi RI. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience. Clin Transplant 2015;29:425-33. [DOI: 10.1111/ctr.12534] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
91 Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008;21:1107-1117. [PMID: 18713148 DOI: 10.1111/j.1432-2277.2008.00735.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
92 Hollebecque A, Decaens T, Boleslawski E, Mathurin P, Duvoux C, Pruvot FR, Dharancy S. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol. 2009;33:361-369. [PMID: 19398289 DOI: 10.1016/j.gcb.2009.02.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
93 Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587-2596. [PMID: 17868066 DOI: 10.1111/j.1600-6143.2007.01965.x] [Cited by in Crossref: 348] [Cited by in F6Publishing: 304] [Article Influence: 24.9] [Reference Citation Analysis]
94 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 98] [Article Influence: 23.6] [Reference Citation Analysis]
95 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
96 Marsh JW, Gray E, Ness R, Starzl TE. Complications of right lobe living donor liver transplantation. J Hepatol. 2009;51:715-724. [PMID: 19576652 DOI: 10.1016/j.jhep.2009.04.023] [Cited by in Crossref: 110] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
97 Okuno T, Ueda M, Tsuruyama T, Haga H, Takada Y, Maetani Y, Tamaki K, Manabe T, Tanaka K, Uemoto S. Loss of heterozygosity on 10q23 is involved in metastatic recurrence of hepatocellular carcinoma. Cancer Sci. 2009;100:520-528. [PMID: 19077004 DOI: 10.1111/j.1349-7006.2008.01056.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
98 Moon JI, Kwon CH, Joh JW, Choi GS, Jung GO, Kim JM, Shin M, Choi SJ, Kim SJ, Lee SK. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival. Transplant Proc. 2012;44:487-493. [PMID: 22410053 DOI: 10.1016/j.transproceed.2011.11.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
99 Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy. J Surg Res 2010;159:538-44. [PMID: 19111323 DOI: 10.1016/j.jss.2008.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
100 Woo HY, Yoo SY, Heo J. Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma. Molecules 2021;26:E295. [PMID: 33435572 DOI: 10.3390/molecules26020295] [Reference Citation Analysis]
101 Morris-stiff G, Gomez D, de Liguori Carino N, Prasad K. Surgical management of hepatocellular carcinoma: Is the jury still out? Surgical Oncology 2009;18:298-321. [DOI: 10.1016/j.suronc.2008.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
102 Hwang S, Lee S, Joh J, Suh K, Kim D. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: Comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-72. [DOI: 10.1002/lt.20549] [Cited by in Crossref: 162] [Cited by in F6Publishing: 144] [Article Influence: 10.1] [Reference Citation Analysis]
103 Brown KA. Liver transplantation. Curr Opin Gastroenterol 2005;21:331-6. [PMID: 15818154 DOI: 10.1097/01.mog.0000159830.36793.2b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
104 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3775] [Article Influence: 256.5] [Reference Citation Analysis]
105 Schwartz M, D'amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? European Journal of Surgical Oncology (EJSO) 2008;34:256-62. [DOI: 10.1016/j.ejso.2007.07.208] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
106 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
107 Theodoropoulos J, Brooks A. Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol. The American Surgeon 2011;77:207-14. [DOI: 10.1177/000313481107700223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12:1747-1754. [PMID: 17133591 DOI: 10.1002/lt.21018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
109 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
110 Mikoshiba N, Tateishi R, Tanaka M, Sakai T, Blazeby JM, Kokudo N, Koike K, Kazuma K. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). Health Qual Life Outcomes 2012;10:58. [PMID: 22651810 DOI: 10.1186/1477-7525-10-58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
111 Ng KK, Lo CM, Chan SC, Chok KS, Cheung TT, Fan ST. Liver transplantation for hepatocellular carcinoma: the Hong Kong experience. J Hepatobiliary Pancreat Sci. 2010;17:548-554. [PMID: 19760139 DOI: 10.1007/s00534-009-0165-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
112 Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598-609. [PMID: 17462459 DOI: 10.1016/j.surg.2006.11.006] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
113 Shindoh J, Vauthey JN. Staging of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:313-322. [PMID: 24560112 DOI: 10.1016/j.soc.2013.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
114 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
115 Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, Teperman LW, Park JS, Kim YJ, Suh KS, Yoon JH. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg. 2016;263:842-850. [PMID: 26779979 DOI: 10.1097/sla.0000000000001578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 11.8] [Reference Citation Analysis]
116 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 177] [Article Influence: 16.5] [Reference Citation Analysis]
117 Tan HP, Patel-Tom K, Marcos A. Adult living donor liver transplantation: who is the ideal donor and recipient? J Hepatol 2005;43:13-7. [PMID: 15925424 DOI: 10.1016/j.jhep.2005.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
118 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, Shimamura T, Furukawa H, Matsushita M, Todo S. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol. 2009;16:1560-1571. [PMID: 19259739 DOI: 10.1245/s10434-009-0407-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 6.0] [Reference Citation Analysis]
119 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
120 Mizuno S, Yokoi H, Shiraki K, Usui M, Sakurai H, Tabata M, Sugimoto K, Takei Y, Yamakado K, Takeda K. Prospective study on the outcome of patients with hepatocellular carcinoma registered for living donor liver transplantation: how long can they wait? Transplantation. 2010;89:650-654. [PMID: 20048691 DOI: 10.1097/TP.0b013e3181cd4ae9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
121 Kyoden Y, Tamura S, Sugawara Y, Yamashiki N, Matsui Y, Togashi J, Kaneko J, Kokudo N, Makuuchi M. Outcome of living donor liver transplantation for post-Kasai biliary atresia in adults. Liver Transpl 2008;14:186-92. [DOI: 10.1002/lt.21344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
122 Shinkawa H, Tanaka S, Takemura S, Amano R, Kimura K, Kinoshita M, Miyazaki T, Kubo S. Prognostic value of expanded liver transplantation criteria-the 5-5-500 rule-in patients with hepatic resection for intermediate-stage hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2020;27:682-9. [PMID: 32578373 DOI: 10.1002/jhbp.792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, Terai S, Sakaida I. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol 2011;46:359-66. [DOI: 10.1007/s00535-010-0306-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
124 Lee S, Song GW, Kim KW, Kwon JH, Lee SG. Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma Within or Beyond the Milan Criteria: Comparable Long-Term Outcomes. Transplant Proc 2021;53:92-7. [PMID: 33288309 DOI: 10.1016/j.transproceed.2020.10.012] [Reference Citation Analysis]
125 Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531-537. [PMID: 19307789 DOI: 10.1097/tp.0b013e3181943bee] [Cited by in Crossref: 113] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
126 Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Wakabayashi G. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports. Transplant Proc. 2011;43:2800-2805. [PMID: 21911167 DOI: 10.1016/j.transproceed.2011.06.063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
127 Xiao GQ, Liu C, Liu DL, Yang JY, Yan LN. Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. World J Gastroenterol. 2013;19:8398-8407. [PMID: 24363533 DOI: 10.3748/wjg.v19.i45.8398] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
128 Trevisani F, Garuti F, Cucchetti A, Lenzi B, Bernardi M. De novo hepatocellular carcinoma of liver allograft: a neglected issue. Cancer Lett. 2015;357:47-54. [PMID: 25444925 DOI: 10.1016/j.canlet.2014.11.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
129 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
130 de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:1321-1331. [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 6.2] [Reference Citation Analysis]
131 Alshahrani AA, Ha SM, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Cho HD, Kwon JH, Kang SH, Lee SG. Clinical Features and Surveillance of Very Late Hepatocellular Carcinoma Recurrence After Liver Transplantation. Ann Transplant 2018;23:659-65. [PMID: 30237389 DOI: 10.12659/AOT.910598] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
132 Majno P, Giostra E, Morel P, Hadengue A, Mentha G. Management of hepatocellular carcinoma in the waiting list before liver transplantation. Journal of Hepatology 2005;42:S134-43. [DOI: 10.1016/j.jhep.2004.12.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
133 Kayashima H, Toshima T, Okano S, Taketomi A, Harada N, Yamashita Y, Tomita Y, Shirabe K, Maehara Y. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice. J Immunol. 2010;185:698-708. [PMID: 20498356 DOI: 10.4049/jimmunol.0900187] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
134 Wan P, Zhang J, Long X, Li Q, Xu N, Zhang M, Chen X, Han L, Xia Q. Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. Eur J Gastroenterol Hepatol. 2014;26:553-561. [PMID: 24589829 DOI: 10.1097/meg.0000000000000070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
135 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Nojiri K, Omata M, Makuuchi M. Selection of liver-transplant candidates for adult-to-adult living donor liver transplantation as the only surgical option for end-stage liver disease. Liver Transpl 2006;12:1077-83. [DOI: 10.1002/lt.20759] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
136 Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon. 2005;3:210-215. [PMID: 16076007 DOI: 10.1016/s1479-666x(05)80043-5] [Cited by in Crossref: 111] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
137 Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014;20:937-44. [PMID: 24797145 DOI: 10.1002/lt.23902] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
138 Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22:1137-1151. [PMID: 19187872 DOI: 10.1016/j.bpg.2008.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
139 Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9:2362-2371. [PMID: 19656125 DOI: 10.1111/j.1600-6143.2009.02783.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 8.6] [Reference Citation Analysis]
140 Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol. 2014;20:5308-5319. [PMID: 24833861 DOI: 10.3748/wjg.v20.i18.5308] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
141 Yokoi H, Isaji S, Yamagiwa K, Tabata M, Nemoto A, Sakurai H, Usui M, Uemoto S. The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006;13:123-30. [DOI: 10.1007/s00534-005-1018-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
142 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
143 Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never. J Hepatol 2005;43:573-7. [PMID: 16112768 DOI: 10.1016/j.jhep.2005.07.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
144 Broering DC, Walter J, Braun F, Rogiers X. Current Status of Hepatic Transplantation. Current Problems in Surgery 2008;45:587-661. [DOI: 10.1067/j.cpsurg.2008.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
145 Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T, Takami T, Yamamoto N. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015;10:e0126649. [PMID: 25992784 DOI: 10.1371/journal.pone.0126649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
146 Brown RS. Live donors in liver transplantation. Gastroenterology. 2008;134:1802-1813. [PMID: 18471556 DOI: 10.1053/j.gastro.2008.02.092] [Cited by in Crossref: 132] [Cited by in F6Publishing: 96] [Article Influence: 10.2] [Reference Citation Analysis]
147 Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol 2008;43:18-26. [DOI: 10.1007/s00535-007-2141-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
148 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
149 Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:1226-1236. [PMID: 22685095 DOI: 10.1002/lt.23490] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
150 Majno P, Mentha G, Toso C; for the Geneva Liver Cancer Study Group. Transplantation for hepatocellular carcinoma: Management of patients on the waiting list. Liver Transpl 2010;16:S2-S11. [DOI: 10.1002/lt.22163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007;25:310-312. [PMID: 17960065 DOI: 10.1159/000106910] [Cited by in Crossref: 156] [Cited by in F6Publishing: 151] [Article Influence: 11.1] [Reference Citation Analysis]
152 Yao FY. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Hepatol Res. 2007;37 Suppl 2:S267-S274. [PMID: 17877493 DOI: 10.1111/j.1872-034x.2007.00195.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
153 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 162] [Article Influence: 28.2] [Reference Citation Analysis]
154 Kogure T, Ueno Y, Kawagishi N, Kanno N, Yamagiwa Y, Fukushima K, Satomi S, Shimosegawa T. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol 2006;41:1005-10. [PMID: 17096070 DOI: 10.1007/s00535-006-1887-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
155 Dutkowski P, Linecker M, Deoliveira ML, Müllhaupt B, Clavien P. Challenges to Liver Transplantation and Strategies to Improve Outcomes. Gastroenterology 2015;148:307-23. [DOI: 10.1053/j.gastro.2014.08.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 120] [Article Influence: 22.5] [Reference Citation Analysis]
156 Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, Tashiro H, Shimamoto F, Asahara T. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007;95:311-316. [PMID: 17326126 DOI: 10.1002/jso.20661] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
157 Fan ST. Live donor liver transplantation in adults. Transplantation. 2006;82:723-732. [PMID: 17006315 DOI: 10.1097/01.tp.0000235171.17287.f2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
158 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
159 Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther. 2010;31:415-423. [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
160 Kishi Y, Hasegawa K, Sugawara Y, Kokudo N. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol. 2011;2011:728103. [PMID: 21994868 DOI: 10.4061/2011/728103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
161 Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, Tatsumi C, Minami Y, Ueshima K, Fukunaga T. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation. Dig Dis. 2007;25:303-309. [PMID: 17960064 DOI: 10.1159/000106909] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
162 Sotiropoulos GC, Kuehl H, Sgourakis G, Molmenti EP, Beckebaum S, Cicinnati VR, Baba HA, Schmitz KJ, Broelsch CE, Lang H. Pulmonary nodules at risk in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant International 2008;21:850-6. [DOI: 10.1111/j.1432-2277.2008.00688.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
163 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 192] [Article Influence: 40.3] [Reference Citation Analysis]
164 Civan JM. Liver Transplantation for HCC: The Milan Criteria. In: Doria C, editor. Contemporary Liver Transplantation. Cham: Springer International Publishing; 2016. pp. 1-19. [DOI: 10.1007/978-3-319-05543-5_11-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
165 Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17 Suppl 2:S58-S66. [PMID: 21584928 DOI: 10.1002/lt.22336] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
166 Lin SY, Lin CL, Hsu WH, Wang IK, Lin CC, Jeng LB, Kao CH. Risk of biliary tract disease in living liver donors: A population-based cohort study. PLoS One 2020;15:e0230840. [PMID: 32226025 DOI: 10.1371/journal.pone.0230840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, Patch D, Davidson BR, Rolles K, Burroughs AK. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation. 2006;81:1532-1541. [PMID: 16770242 DOI: 10.1097/01.tp.0000209641.88912.15] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
168 Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S. Living Donor Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings 2012;44:1713-6. [DOI: 10.1016/j.transproceed.2012.05.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
169 Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007;204:1-6. [PMID: 17189106 DOI: 10.1016/j.jamcollsurg.2006.10.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
170 Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008;14:935-945. [PMID: 18581465 DOI: 10.1002/lt.21445] [Cited by in Crossref: 206] [Cited by in F6Publishing: 189] [Article Influence: 15.8] [Reference Citation Analysis]
171 Yang SH, Suh K, Lee HW, Cho E, Cho JY, Cho YB, Yi N, Lee KU. The role of18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-60. [DOI: 10.1002/lt.20861] [Cited by in Crossref: 112] [Cited by in F6Publishing: 96] [Article Influence: 7.5] [Reference Citation Analysis]
172 Makuuchi M, Sugawara Y. Current status of liver transplantation for hepatocellular carcinoma from living donors. Hepatology Research 2007;37:S277-8. [DOI: 10.1111/j.1872-034x.2007.00197.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
173 Nadalin S, Bockhorn M, Malagó M, Valentin-Gamazo C, Frilling A, Broelsch CE. Living donor liver transplantation. HPB (Oxford). 2006;8:10-21. [PMID: 18333233 DOI: 10.1080/13651820500465626] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
174 Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol. 2007;8:320-327. [PMID: 17673843 DOI: 10.3348/kjr.2007.8.4.320] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
175 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Reference Citation Analysis]
176 Mittler J, Pascher A, Jonas S, Pratschke J, Neumann UP, Langrehr JM, Neuhaus P. Adult living donor liver transplantation: living donation of the right liver lobe. Langenbecks Arch Surg. 2007;392:657-662. [PMID: 17443341 DOI: 10.1007/s00423-007-0187-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
177 Huang H, Lee F, Huo T. Major adverse events, pretransplant assessment and outcome prediction. Journal of Gastroenterology and Hepatology 2009;24:1716-24. [DOI: 10.1111/j.1440-1746.2009.06025.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
178 Roayaie S, Llovet JM. Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified? Clinics in Liver Disease 2005;9:315-28. [DOI: 10.1016/j.cld.2004.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
179 Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C, Ikeda M, Ueno H, Okusaka T, Arai Y, Takayasu K. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14:2337-2347. [PMID: 17503155 DOI: 10.1245/s10434-007-9415-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
180 Hackl C, Schlitt HJ, Melter M, Knoppke B, Loss M. Current developments in pediatric liver transplantation. World J Hepatol. 2015;7:1509-1520. [PMID: 26085910 DOI: 10.4254/wjh.v7.i11.1509] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
181 Ioannou GN, Perkins JD, Carithers RL. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:1342-1351. [PMID: 18471511 DOI: 10.1053/j.gastro.2008.02.013] [Cited by in Crossref: 193] [Cited by in F6Publishing: 175] [Article Influence: 14.8] [Reference Citation Analysis]
182 Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma. Ann Surg Oncol 2011;18:2200-9. [PMID: 21301972 DOI: 10.1245/s10434-011-1577-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
183 Fujiki M, Aucejo F, Kim R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this? Clin Transplant 2013;27:169-77. [PMID: 23216662 DOI: 10.1111/ctr.12042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
184 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
185 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
186 Sá GP, Vicentine FP, Salzedas-Netto AA, Matos CA, Romero LR, Tejada DF, Massarollo PC, Lopes-Filho GJ, Gonzalez AM. LIVER TRANSPLANTATION FOR CARCINOMA HEPATOCELLULAR IN SÃO PAULO: 414 CASES BY THE MILAN/BRAZIL CRITERIA. Arq Bras Cir Dig 2016;29:240-5. [PMID: 28076478 DOI: 10.1590/0102-6720201600040007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
187 Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, Nagata S, Sugimachi K, Gion T, Shirabe K, Maehara Y. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation: De Novo HCC in a Liver Graft with SVR. Liver Transpl 2009;15:1412-6. [DOI: 10.1002/lt.21894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
188 Marubashi S, Dono K, Nagano H, Sugita Y, Asaoka T, Hama N, Miyamoto A, Takeda Y, Umeshita K, Monden M. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation. Transpl Int. 2007;20:576-582. [PMID: 17425725 DOI: 10.1111/j.1432-2277.2007.00480.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
189 Chen J, Xu X, Wu J, Ling Q, Wang K, Wang W, Zhang M, Shen Y, Zhou L, Xie H. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS One. 2014;9:e93128. [PMID: 24676010 DOI: 10.1371/journal.pone.0093128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
190 Yamashita Y, Tsuijita E, Takeishi K, Fujiwara M, Kira S, Mori M, Aishima S, Taketomi A, Shirabe K, Ishida T, Maehara Y. Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol 2012;19:2027-34. [PMID: 22203184 DOI: 10.1245/s10434-011-2195-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.9] [Reference Citation Analysis]
191 Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452. [PMID: 17683486 DOI: 10.1111/j.1440-1746.2007.05075.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
192 Puneet P, Perera MTPR, Mirza DF. Current opinion on the role of resection and liver transplantation for hepatocellular cancer. Indian J Gastroenterol 2012;31:89-99. [DOI: 10.1007/s12664-012-0200-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
193 Kaibori M, Saito T, Matsui Y, Uchida Y, Ishizaki M, Kamiyama Y. A review of the prognostic factors in patients with recurrence after liver resection for hepatocellular carcinoma. Am J Surg 2007;193:431-7. [PMID: 17368283 DOI: 10.1016/j.amjsurg.2006.06.041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
194 Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, Nagorney DM, Belghiti J, Cherqui D, Poon RT, Kokudo N, Vauthey JN. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20:1223-1229. [PMID: 23179993 DOI: 10.1245/s10434-012-2739-y] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 8.9] [Reference Citation Analysis]
195 Polat KY, Acar S, Gencdal G, Yazar S, Kargi A, Donmez R, Aslan S, Kavlak ME, Arikan C, Akyildiz M. Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience. Transplantation Proceedings 2020;52:259-64. [DOI: 10.1016/j.transproceed.2019.10.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
196 Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl. 2007;13:687-692. [PMID: 17457911 DOI: 10.1002/lt.21138] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
197 Kishi Y, Sugawara Y, Tamura S, Kaneko J, Kokudo N, Makuuchi M. Impact of incidentally found hepatocellular carcinoma on the outcome of living donor liver transplantation. Transplant Int 2006;19:720-5. [DOI: 10.1111/j.1432-2277.2006.00338.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
198 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
199 Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H, Arii S. Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery 2010;147:405-14. [DOI: 10.1016/j.surg.2009.09.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
200 White SA, Pollard SG. Living donor liver transplantation. British Journal of Surgery 2005;92:262-3. [DOI: 10.1002/bjs.4939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
201 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
202 Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci. 2010;17:443-448. [PMID: 19885638 DOI: 10.1007/s00534-009-0241-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
203 Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.Ann Surg. 2020;272:855-862. [PMID: 32889867 DOI: 10.1097/SLA.0000000000004280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
204 Itoh S, Morita K, Ueda S, Sugimachi K, Yamashita Y, Gion T, Fukuzawa K, Wakasugi K, Taketomi A, Maehara Y. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol. 2009;16:3299-3307. [PMID: 19826875 DOI: 10.1245/s10434-009-0721-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
205 Andrew Schumacher P, Powell JJ, Macneill AJ, Buczkowski AK, Erb SR, Ho SG, Scudamore CH, Stembrecher UP, Weiss A, Yoshida E, Chung SW. Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation. Annals of Hepatology 2010;9:23-32. [DOI: 10.1016/s1665-2681(19)31675-8] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
206 Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, Ha TY, Song GW. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl. 2007;13:741-746. [PMID: 17457860 DOI: 10.1002/lt.21157] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 6.1] [Reference Citation Analysis]
207 Végső G, Görög D, Fehérvári I, Nemes B, Doros A, Langer RM, Kóbori L. Role of Organ Transplantation in the Treatment of Malignancies – Hepatocellular Carcinoma as the Most Common Tumour Treated with Transplantation. Pathol Oncol Res 2012;18:1-10. [DOI: 10.1007/s12253-011-9441-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
208 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223-10237. [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
209 Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL; A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007;7:1601-1608. [PMID: 17511683 DOI: 10.1111/j.1600-6143.2007.01802.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 160] [Article Influence: 12.5] [Reference Citation Analysis]
210 Zheng W, Zhao KM, Luo LH, Yu Y, Zhu SM. Perioperative Single-Donor Platelet Apheresis and Red Blood Cell Transfusion Impact on 90-Day and Overall Survival in Living Donor Liver Transplantation. Chin Med J (Engl) 2018;131:426-34. [PMID: 29451147 DOI: 10.4103/0366-6999.225049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
211 Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol. 2009;15:4170-4176. [PMID: 19725152 DOI: 10.3748/wjg.15.4170] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
212 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 285] [Article Influence: 35.6] [Reference Citation Analysis]
213 Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Soejima Y. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010;17:2283-2289. [PMID: 20204531 DOI: 10.1245/s10434-010-0999-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
214 Ghobrial RM, Busuttil RW. Challenges of adult living-donor liver transplantation. J Hepatobiliary Pancreat Surg 2006;13:139-45. [DOI: 10.1007/s00534-005-1020-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
215 Lee K, Lee KB, Yi NJ, Suh KS, Jang JJ. Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy. J Pathol Transl Med 2017;51:79-86. [PMID: 28013531 DOI: 10.4132/jptm.2016.10.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
216 Yamamoto J, Kosuge T, Saiura A, Sakamoto Y, Shimada K, Sano T, Takayama T, Sugawara Y, Yamaguchi T, Kokudo N, Makuuchi M. Effectiveness of Hepatic Resection for Early-stage Hepatocellular Carcinoma in Cirrhotic Patients: Subgroup Analysis according to Milan Criteria. Japanese Journal of Clinical Oncology 2007;37:287-95. [DOI: 10.1093/jjco/hym025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
217 Sotiropoulos GC, Lang H, Nadalin S, Neuhäuser M, Molmenti EP, Baba HA, Paul A, Saner FH, Weber F, Hilgard P, Frilling A, Broelsch CE, Malagó M. Liver Transplantation for Hepatocellular Carcinoma: University Hospital Essen Experience and Metaanalysis of Prognostic Factors. Journal of the American College of Surgeons 2007;205:661-75. [DOI: 10.1016/j.jamcollsurg.2007.05.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
218 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamashita K, Taniguchi M, Shimamura T, Matsushita M, Todo S. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg. 2010;211:443-449. [PMID: 20822741 DOI: 10.1016/j.jamcollsurg.2010.06.005] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 10.7] [Reference Citation Analysis]
219 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 7.3] [Reference Citation Analysis]
220 Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course! J Hepatol. 2005;43:569-573. [PMID: 16120470 DOI: 10.1016/j.jhep.2005.07.016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
221 Lerut J. Carcinome hépatocellulaire et transplantation hépatique : état des lieux. Journal de Chirurgie 2007;144:105-10. [DOI: 10.1016/s0021-7697(07)89481-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
223 Gunay Y, Guler N, Yaprak O, Dayangac M, Akyildiz M, Altaca G, Yuzer Y, Tokat Y. Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria. Indian J Surg 2015;77:950-6. [PMID: 27011489 DOI: 10.1007/s12262-014-1078-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
224 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
225 Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008;8:2547-2557. [PMID: 19032223 DOI: 10.1111/j.1600-6143.2008.02409.x] [Cited by in Crossref: 236] [Cited by in F6Publishing: 209] [Article Influence: 19.7] [Reference Citation Analysis]
226 Tohyama T, Sakamoto K, Tamura K, Nakamura T, Watanabe J, Wakisaka H, Takada Y. Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review. World J Surg Oncol 2020;18:109. [PMID: 32466780 DOI: 10.1186/s12957-020-01873-0] [Reference Citation Analysis]
227 Nanashima A, Masuda J, Miuma S, Sumida Y, Nonaka T, Tanaka K, Hidaka S, Sawai T, Nagayasu T. Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World J Gastroenterol 2008;14:58-63. [PMID: 18176962 DOI: 10.3748/wjg.14.58] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
228 Kadry Z, Mc Cormack L, Clavien P. Should living donor liver transplantation be part of every liver transplant program? Journal of Hepatology 2005;43:32-7. [DOI: 10.1016/j.jhep.2005.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
229 Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA. Is Resection or Transplantation the ideal Treatment in Patients with Hepatocellular Carcinoma in Cirrhosis if Both Are Possible? A Systematic Review and Metaanalysis. Ann Surg Oncol 2014;21:3096-107. [DOI: 10.1245/s10434-014-3808-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
230 Quintini C, Hashimoto K, Uso TD, Miller C. Is there an advantage of living over deceased donation in liver transplantation? Transpl Int 2013;26:11-9. [PMID: 22937787 DOI: 10.1111/j.1432-2277.2012.01550.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
231 Hwang S, Moon D, Ahn C, Kim K, Ha T, Song G, Jung D, Park G, Lee H, Lee Y, Chung Y, Abdulkarim B, Lee S. Risk-Based Long-Term Screening for Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation. Transplantation Proceedings 2013;45:3076-84. [DOI: 10.1016/j.transproceed.2013.08.068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
232 Sotiropoulos GC, Paul A, Molmenti E, Lang H, Frilling A, Napieralski BP, Nadalin S, Treckmann J, Brokalaki EI, Gerling T, Broelsch CE, Malagó M. Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants". Transplantation 2005;80:897-902. [PMID: 16249736 DOI: 10.1097/01.tp.0000173644.63692.dc] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
233 Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, Ogawa K, Kasahara M, Oike F, Egawa H. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl. 2006;12:912-919. [PMID: 16489583 DOI: 10.1002/lt.20642] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 4.3] [Reference Citation Analysis]
234 Yamashiki N, Yoshida H, Tateishi R, Shiina S, Teratani T, Yoshida H, Kondo Y, Oki T, Kawabe T, Omata M. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J Gastroenterol Hepatol 2007;22:2155-60. [DOI: 10.1111/j.1440-1746.2006.04732.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
235 Izumi N, Asahina Y, Tsuchiya K, Kurosaki M, Nakanishi H, Kitamura T, Uchihara M, Miyake S. Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatology Research 2007;37:S254-63. [DOI: 10.1111/j.1872-034x.2007.00193.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
236 Cucchetti A, Cescon M, Bertuzzo V, Bigonzi E, Ercolani G, Morelli MC, Ravaioli M, Pinna AD. Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation? Am J Transplant 2011;11:1696-704. [PMID: 21668632 DOI: 10.1111/j.1600-6143.2011.03570.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
237 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
238 Nathan H, Segev DL, Mayo SC, Choti MA, Cameron AM, Wolfgang CL, Hirose K, Edil BH, Schulick RD, Pawlik TM. National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer 2012;118:1838-44. [DOI: 10.1002/cncr.26501] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
239 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
240 Nakagawa T, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, Todo S. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg. 2006;131:1248-1254. [PMID: 16733153 DOI: 10.1016/j.jtcvs.2006.02.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
241 Suh YJ, Kim MJ, Choi JY, Park MS, Kim KW. Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging. Liver Transpl 2012;18:1171-8. [PMID: 22767394 DOI: 10.1002/lt.23502] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 8.1] [Reference Citation Analysis]
242 Song GW, Hwang S, Lee SG. [Liver transplantation in patients with hepatocellular carcinoma]. Korean J Gastroenterol. 2010;55:350-360. [PMID: 20571302 DOI: 10.4166/kjg.2010.55.6.350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
243 Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012;18:423-433. [PMID: 22250078 DOI: 10.1002/lt.23385] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
244 Durand F, Belghiti J, Troisi R, Boillot O, Gadano A, Francoz C, de Hemptinne B, Mallet A, Valla D, Golmard JL. Living donor liver transplantation in high-risk vs. low-risk patients: Optimization using statistical models. Liver Transpl 2006;12:231-9. [DOI: 10.1002/lt.20700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
245 Ikegami T, Shimada M, Imura S, Yoshizumi T, Arakawa Y, Tokunaga T, Morine Y, Kanemura H. The timing of liver transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria. Transplantation. 2008;86:641-646. [PMID: 18791443 DOI: 10.1097/tp.0b013e3181814de2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
246 Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, Hsu CN, Lin CL, Kao CH. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med. 2017;42:e183-e187. [PMID: 28114226 DOI: 10.1097/rlu.0000000000001545] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
247 Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416-427. [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025] [Cited by in Crossref: 132] [Cited by in F6Publishing: 119] [Article Influence: 18.9] [Reference Citation Analysis]
248 Saito R, Amemiya H, Hosomura N, Kawaida H, Maruyama S, Shimizu H, Furuya S, Akaike H, Kawaguchi Y, Sudo M, Inoue S, Kono H, Ichikawa D. Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection. In Vivo 2020;34:1265-70. [PMID: 32354917 DOI: 10.21873/invivo.11900] [Reference Citation Analysis]
249 Lee SG. Asian contribution to living donor liver transplantation. J Gastroenterol Hepatol. 2006;21:572-574. [PMID: 16638101 DOI: 10.1111/j.1440-1746.2006.04283.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
250 Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, Park KM, Song GW, Jung DH, Kim BS. Small-sized liver graft does not increase the risk of hepatocellular carcinoma recurrence after living donor liver transplantation. Transplant Proc. 2007;39:1526-1529. [PMID: 17580180 DOI: 10.1016/j.transproceed.2007.03.066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
251 Martin AP. Management of hepatocellular carcinoma in the age of liver transplantation. Int J Surg 2009;7:324-9. [PMID: 19643691 DOI: 10.1016/j.ijsu.2008.12.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
252 Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst Rev 2013;:CD006935. [PMID: 23813393 DOI: 10.1002/14651858.CD006935.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
253 Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel) 2019;11:E1295. [PMID: 31484287 DOI: 10.3390/cancers11091295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
254 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
255 Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36 Suppl 1:124-129. [PMID: 26725909 DOI: 10.1111/liv.13028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
256 Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg. 2012;74:100-117. [PMID: 23372314 DOI: 10.1007/s12262-011-0387-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
257 Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria: Expanded Criteria for LT in HCC. Liver Transpl 2008;14:272-8. [DOI: 10.1002/lt.21368] [Cited by in Crossref: 101] [Cited by in F6Publishing: 89] [Article Influence: 7.8] [Reference Citation Analysis]